Introduction {#s1}
============

Type 1 diabetes (T1D) and celiac disease (CeD) are immunologic disorders, affecting between 0.5% and 1% of the general population ([@B1],[@B2]). They are both multifactorial diseases arising from a combination of multiple genetic and environmental factors. In addition, these two diseases co-occur in families, and even in single patients, more often than expected by chance ([@B3]). Approximately 4--9% of patients with T1D also have CeD ([@B4]), while patients with CeD are at increased risk of developing T1D ([@B5]). Since the genetic contribution within each disease is high, there may be an overlap in their etiology due to shared genetic risk factors ([@B6]) or due to synergistic effects of the genes involved in each disease separately ([@B7]).

Both T1D and CeD are seen mainly in populations of European ancestry, although they occur at a lower prevalence in African, Asian, and Latin American populations ([@B2],[@B8],[@B9]). The underlying autoimmune processes share some features, but the autoreactive T cells and autoantibodies are directed against different autoantigens: insulin, GADA65, and IA-2 in T1D and tissue transglutaminase and endomysial antibody in CeD ([@B10]). In most patients, preislet and celiac autoimmunity develop in early childhood, although both diseases can also develop later in life ([@B11],[@B12]).

The class II genes explain a major component of familial clustering in both T1D and CeD, in particular the *HLA-DRB1, HLA-DQA1*, and *HLA-DQB1* genes ([@B13]). For T1D, alleles of HLA class II genes can confer both disease susceptibility and disease protection. Individuals carrying both the DR3-DQ2 (DRB1\*03-DQB1\*0201) and DR4-DQ8 haplotype (DRB1\*04-DQB1\*0302) are at the highest risk for developing T1D ([@B14]). Its presence marks a 55% risk of developing overt diabetes by age 12 years ([@B15]); however, only 20--50% of patients with T1D carry this genotype. For CeD, the most prominent association is with *HLA-DQ2.5* (DQA1\*0501-DQB1\*0201) ([@B16]). Individuals homozygous for the DQB1\*02 allele (i.e., carriers of *DQ2.5*/*DQ2.5* and *DQ2.5*/*DQ2.2*) are at high risk of developing CeD ([@B17]).

Genome-wide association studies (GWAS) have revolutionized the identification of additional predisposing risk factors to these diseases outside the HLA region. To date, more than 40 non-HLA loci for T1D and 26 non-HLA loci for CeD have been identified by GWAS (summarized at [www.t1dbase.org](http://www.t1dbase.org) \[[@B18]--[@B20]\]). It is noteworthy that many of the non-HLA loci are shared between various autoimmune diseases ([@B7],[@B21]). GWAS and cross-disease studies have identified the same regions, or even the same single nucleotide polymorphisms (SNPs), as associated with both T1D and CeD, including the *HLA, TAGAP, IL18RAP, SH2B3, CTLA4, CCR5, IL2/21, BACH2, UBASH3A*, and *PTPN2* loci ([@B7],[@B22]).

Individuals affected by more than one autoimmune disorder may have an immune response more disturbed than those with only one disease. Specific genetic factors already identified as contributors to risk of T1D and CeD individually could be critical for double autoimmunity. Thus, our aim was to examine the genetic differences between individuals developing both T1D and CeD with respect to the genetic risk associated with having only one of these diseases.

Research Design and Methods {#s2}
===========================

Patients and Control Participants {#s3}
---------------------------------

Informed consent was obtained for all samples used, and the project was approved by the ethics committees of each of the institutions involved. T1D-only samples were collected from the Type 1 Diabetes Genetics Consortium (T1DGC), and CeD-only samples were collected from previous studies ([@B19],[@B23],[@B24]). Samples from individuals with both T1D and CeD (double autoimmunity) were collected from T1DGC, the Barbara Davis Center, and the VU University Medical Centre (Amsterdam, the Netherlands) ([Table 1](#T1){ref-type="table"}). The identification of T1D only was based on self-reports, evaluation of medical records, and, when indicated, C-peptide determination using a standard protocol of the T1DGC.

###### 

Samples and data sets used in our analyses

                                  Double autoimmunity case subjects   Control subjects with T1D only   Control subjects with CeD only   Total
  ------------------------------- ----------------------------------- -------------------------------- -------------------------------- -------
  Origin (by center)                                                                                                                    
   Barbara Davis Center           313                                                                                                   313
   T1DGC                          147                                 2,472                                                             2,619
   VU University Medical Centre   51                                                                                                    51
   UMCG                           32                                                                   2,223                            2,255
  Origin (by country)                                                                                                                   
   U.S.                           460                                 2,472                                                             2,932
   The Netherlands                83                                                                   1,134                            1,217
   U.K.                                                                                                1,089                            1,089

The identification of double autoimmunity individuals among patients first diagnosed with T1D was based initially upon self-reporting and confirmed by having high and persistent levels of IgA transglutaminase (IgA tissue transglutaminase) autoantibodies or confirmed by biopsy ([@B25]). T1D was identified in patients first diagnosed with CeD according to the guidelines of an American Diabetes Association position statement ([@B26]). The patients with CeD only were identified with autoantibody testing, confirmed by an intestinal biopsy ([@B27]). Control subjects of Caucasian ancestry were also included ([@B23]). In total, 543 individuals with double autoimmunity were identified, 3,098 patients with T1D only, 12,480 CeD-only patients, and 11,023 control subjects. All samples were genotyped using the ImmunoChip ([@B23]). The hybridization and processing of the CeD samples and part of the double autoimmunity samples (those not from T1DGC) were performed in the Department of Genetics, University Medical Centre Groningen (UMCG), while the genotyping of the T1D samples and the double autoimmunity samples from T1DGC was performed at the Genome Sciences Laboratory in the Center for Public Health Genomics at the University of Virginia. A total of 28 non-HLA SNPs associated with CeD and 42 SNPs with T1D were selected, all at genome-wide significance (*P* \< 5 × 10^−8^) ([@B19],[@B20],[@B23],[@B28]--[@B33]). After quality control, 66 SNPs remained for our analysis: 21 non-HLA SNPs associated with CeD-only, 33 SNPs associated with T1D-only, and 12 SNPs from eight loci shared between the two diseases ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dcS15-2007/-/DC1)). For prediction of whether an individual carries *HLA-DQ2* (*DQ2.5* or *DQ2.2*) and/or *DQ8* alleles, five of the six tagging SNPs described by Monsuur et al. ([@B34]) were used. We failed to predict the *HLA*-*DQ7* haplotype, as the sixth SNP (rs4639334) failed quality-control metrics.

Study Groups and Quality Control {#s4}
--------------------------------

Two data sets were assembled and two independent analyses performed to identify SNPs contributing to double autoimmunity. Individuals in the first analysis consisted of "case" subjects with double autoimmunity and "control" subjects with T1D only (T1D+CeD/T1D). Individuals in the second analysis consisted of "case" subjects with double autoimmunity and "control" subjects with CeD only (T1D+CeD/CeD).

The quality-control assessment protocols were conducted for each study group independently. Individuals were excluded with call rate \<99.5% or sex inconsistency or if there was a first- or second-degree relationship with the index case. SNPs were excluded with a genotyping rate \<99%, minor allele frequency \<0.05%, and failure of Hardy-Weinberg equilibrium assumptions (*P* \< 5 × 10^−6^). The latter analysis was performed using KING, version 1.4, software ([@B35]). Owing to the different ethnic backgrounds present in the sample (samples from North America, Europe, U.K., and Asia Pacific in the T1DGC data set and from Europe and India in the CeD data set), a principal components analysis was applied to each of the data sets with the aim of identifying and excluding possible ethnicity outliers and to reduce the possibility of population stratification. This analysis was performed sequentially using EIGENSTRAT, version 4.2, software ([@B36]) and removing outliers at each step. After quality control, the data set included 2,955 individuals for the T1D+CeD/T1D analysis (1,451 males and 1,504 females) and 2,655 individuals for the T1D+CeD/CeD analysis (865 males and 1,790 females)---all the samples with Caucasian origin.

Statistical Analysis {#s5}
--------------------

The association analysis was conducted separately for HLA and non-HLA risk loci. For the HLA locus, the analysis was performed on the predicted haplotypes and genotypes of *DQ2.5* (DQA1\*0501, DQB1\*0201, and DRB1\*03), *DQ2.2* (DQA1\*0201, DQB1\*0202, and DRB1\*07), and *DQ8* (DQA1\*03, DQB1\*0302, and DRB1\*04) and including the first five principal components as covariates. These haplotypes are well-known risk factors for both T1D and CeD. The absence of any of these haplotypes was classified as "other." The HLA analyses were divided into an analysis of the number of haplotypes per individual (whether an individual was carrying 0, 1, or 2 copies of the tested haplotype) and of genotypes (whether an individual was carrying combinations of risk haplotypes).

Association analyses were performed for each study group using a genetic-based matching score. Pairwise comparisons of identity by descent were calculated for all samples, and then individuals were matched and clustered in homogeneous groups of case and control subjects to reduce false-positive associations owing to population stratification. With the results from the calculated clusters, a Cochran-Mantel-Haenszel analysis was performed, correcting the association for the genomic control inflation factor (λ). Nominal statistical significance of *P* \< 0.05 was used as the threshold for association, as the analyzed SNPs had been associated in previous GWAS and replicated at genome-wide significance. The analyses were performed using PLINK, version 1.07, and the statistical suite R, version 3.1.0 ([@B37],[@B38]).

Results {#s6}
=======

After completion of quality-control procedures and removal of outliers, a total of 2,955 samples (483 case and 2,472 control subjects) were included for the first T1D+CeD/T1D analysis; a total of 2,655 samples were included for T1D+CeD/CeD analysis (432 case and 2,223 control subjects). There was no evidence of significant inflation in the results of association (λ~T1D+CeD/T1D~ = 0.99; λ~T1D+CeD/CeD~ = 1.04) for either set of analyses ([Fig. 1](#F1){ref-type="fig"}).

![Principal components and Q-Q plot of each group of analyses. The principal components analysis was used to cluster the most homogeneous samples for association analysis. The shape of the clusters differs because of the different origins of the merged samples; however, it is still possible to observe a good match between case and control subjects. *A*: Double autoimmunity vs. CeD-only patients. *B*: Double autoimmunity vs. patients with T1D only. PC1, principal component 1; PC2, principal component 2.](dcs152007f1){#F1}

Comparing Known Risk Alleles Across Diseases {#s7}
--------------------------------------------

We first aimed to investigate the status of established CeD and T1D loci across the published GWAS data sets ([@B19],[@B20],[@B28]--[@B33]) considering only those loci with at least one reported risk allele--associated genome-wide significance (*P* \< 5 × 10^−8^) and confirmation in independent samples. Across 28 non-HLA SNPs from CeD and 42 non-HLA SNPs from T1D, representing 60 distinct risk loci, eight loci (represented by 12 SNPs) are shared between both diseases ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dcS15-2007/-/DC1)). Four of the reported SNPs in CeD and/or T1D (rs13010713-*ITGA4*, rs11755527-*BACH2*, rs1265564-*CUX2*, and rs917997-*IL18RAP*) were removed based on quality-control metrics, with one SNP proxy inserted (rs917997 was replaced by rs7559479 for *IL18RAP*). In total, 66 SNPs were included in the association analysis.

Genetic Association in Double Autoimmunity Patients {#s8}
---------------------------------------------------

Results of the association analysis for each of the 66 SNPs that passed our quality control in the two diseases are shown in [Fig. 2](#F2){ref-type="fig"} (odds ratio \[OR\] and 95% CI). Of the 21 CeD-only SNPs, 6 (28.6%) were associated (*P* \< 0.05) with risk of double autoimmunity ([Table 2](#T2){ref-type="table"}). Similarly, of 33 T1D-only SNPs, 8 (24.2%) from six loci were associated (*P* \< 0.05) with double autoimmunity ([Table 3](#T3){ref-type="table"}).

![ORs and CIs for all the variants evaluated. ORs and 95% CIs for all the SNPs associated with CeD, T1D, or both that passed our quality controls. *A*: Double autoimmunity vs. T1D. *B*: Double autoimmunity vs. CeD. Highlighted markers correspond with those with a significant *P* value: \<0.05. It was not possible to detect an enrichment of CeD or T1D variants associated with double autoimmunity based on the analysis of both data sets.](dcs152007f2){#F2}

###### 

Association of previously described variants for CeD and T1D in the data set of double autoimmunity versus CeD-only patients

  Chr   SNP          Position    A1   Allele freq.   OR (95% CI)         *P*            Reported disease   Risk allele   OR reported   *P* reported   Gene reported                     Ref
  ----- ------------ ----------- ---- -------------- ------------------- -------------- ------------------ ------------- ------------- -------------- --------------------------------- ---------------
  3     rs17810546   161147744   G    0.16           0.72 (0.57, 0.92)   0.022          CeD                G             1.36          4 × 10^−28^    *IL12A*                           [@B19]
  10    rs1250552    80728033    G    0.44           1.24 (1.05, 1.46)   0.020          CeD                NR            1.12          9 × 10^−10^    *ZMIZ1*                           [@B19]
  2     rs3087243    204447164   G    0.58           1.41 (1.30, 1.55)   0.001          T1D+CeD            A             NR            8 × 10^−11^    *CTLA4*                           [@B20],[@B22]
  12    rs17696736   110971201   G    0.47           1.22 (1.03, 1.45)   0.036          T1D+CeD            G             1.34          2 × 10^−14^    *SH2B3*/*LNK*/*TRAFD1*/*PTPN11*   [@B20]
  1     rs2476601    114179091   A    0.12           2.16 (1.72, 2.72)   2.4 × 10^−9^   T1D                T             1.98          2 × 10^−80^    *PTPN22*                          [@B20]
  10    rs61839660   6134703     T    0.09           0.55 (0.39, 0.76)   0.001          T1D                NR            1.6           5 × 10^−9^     *IL2RA*                           [@B20]
  11    rs1004446    2126719     C    0.61           1.68 (1.58, 1.79)   1.2 × 10^−7^   T1D                C             1.61          4 × 10^−9^     *INS*                             [@B22]
  11    rs7111341    2169742     T    0.27           0.66 (0.54, 0.81)   4.6 × 10^−4^   T1D                NR            NR            4 × 10^−48^    *INS*                             [@B20]
  12    rs11171739   54756892    C    0.43           1.23 (1.04, 1.45)   0.026          T1D                C             1.34          1 × 10^−11^    *ERBB3*                           [@B33]
  16    rs12708716   11087374    A    0.64           1.24 (1.11, 1.39)   0.034          T1D                G/A           NR            7 × 10^−13^    *CLEC16A*/*KIAA0350*              [@B22]
  16    rs4788084    28447349    G    0.57           1.21 (1.08, 1.37)   0.049          T1D                G             1.09          3 × 10^−13^    *IL27*                            [@B20]

A1, allele associated; Allele freq., allele frequency for which OR is reported; Chr, chromosome; Gene reported, the most plausible gene reported by the literature; NR, not reported; Position, position in base pair; Ref, reference.

###### 

Association of previously described variants for CeD and T1D in the data set of double autoimmunity versus patients with T1D only

  Chr   SNP          Position    A1   Allele freq.   OR (95% CI)         *P*        Reported disease   Risk allele   OR reported   *P* reported   Gene reported           Ref
  ----- ------------ ----------- ---- -------------- ------------------- ---------- ------------------ ------------- ------------- -------------- ----------------------- ---------------
  1     rs2816316    190803436   A    0.83           1.32 (1.15, 1.53)   0.03086    CeD                A             1.25          2 × 10^−17^    *RGS1*                  [@B19]
  2     rs4675374    204510823   A    0.23           1.33 (1.08, 1.64)   0.00728    CeD                A             1.14          6 × 10^−9^     *CTLA4*/*ICOS*/*CD28*   [@B19]
  3     rs11712165   120601486   C    0.38           1.22 (1.01, 1.46)   0.03101    CeD                C             1.13          8 × 10^−9^     *CD80*/*KTELC1*         [@B19]
  3     rs1464510    189595248   A    0.46           1.28 (1.07, 1.54)   0.006945   CeD                A             1.29          3 × 10^−40^    *LPP*                   [@B19]
  2     rs3087243    204447164   G    0.61           1.36 (1.23, 1.51)   0.00126    T1D+CeD            G             1.15          8 × 10^−11^    *CTLA4*                 [@B20],[@B22]
  10    rs12251307   6163501     T    0.09           1.46 (1.06, 2.0)    0.01756    T1D                T             NR            1 × 10^−13^    *IL2RA*                 [@B20]

A1, allele associated; Allele freq., allele frequency for which OR is reported; Chr, chromosome; Gene reported, the most plausible gene reported by the literature; Position, position in base pair; Ref, reference.

Of the 12 SNPs in eight loci that were shared across T1D and CeD, 10 SNPs (representing seven loci) exhibited the same trend of effect compared with the effect on individual disease risk in previous T1D or CeD GWAS. The *IL12A* locus SNP rs17810546 had an opposite effect in the double autoimmunity group (OR~T1D+CeD/CeD~ 0.72; minor allele frequency 0.16, *P* = 0.022) than in the CeD GWAS (OR 1.36). There was only one locus shared between T1D and CeD (*CTLA4* \[rs3087243\]) that was associated in both T1D+CeD/T1D (*P* = 0.001) and T1D+CeD/CeD (*P* = 0.0006). The association of double autoimmunity with *IL2RA* differed in the SNP for the two groups, with rs61839660 in T1D+CeD/CeD (*P* = 0.001) but rs12251307 in T1D+CeD/T1D (*P* = 0.0175). These two SNPs are in linkage disequilibrium (*r*^2^ = 0.543, D′ = 0.84); however, rs61839660 is located intronic in *IL2RA*, while rs12251307 is 5′ of the same gene.

Association of HLA Loci {#s9}
-----------------------

None of the HLA haplotypes (*HLA-DQ2.5*, *HLA-DQ2.2*, or *HLA-DQ8*) were statistically significant for association of double autoimmunity with respect to CeD only (T1D+CeD/CeD). The *HLA-DQ8* haplotype had the highest risk for double autoimmunity, though not significant, when the double autoimmunity individuals were compared with those with CeD only (OR 5.09, *P* = 0.16). In contrast, the *HLA-DQ2.5* haplotype was significantly associated (*P* = 0.0003) with double autoimmunity relative to T1D only (OR 1.44). There was absence of association of double autoimmunity with "other" HLA risk haplotypes ([Table 4](#T4){ref-type="table"}).

T1D+CeD/CeD analysis identified a significant association with the heterozygote genotype *DQ2.5*/*DQ8* (OR 1.47, *P* = 3.31 × 10^−10^) ([Table 4](#T4){ref-type="table"}). In the double autoimmunity group, we identified the haplotype *DQ2.5*/*DQ2.5* (OR 1.2, *P* = 0.005) as significantly associated with risk compared with T1D only ([Table 4](#T4){ref-type="table"}).

###### 

Haplotype and genotype HLA association and frequency comparison between healthy control subjects and patients with double autoimmunity, T1D only, or CeD only

                     Freq. control subjects   T1D+CeD/CeD   T1D+CeD/T1D                                                                            
  ------------------ ------------------------ ------------- ------------- ---------------------- ---------- ------- ------- ---------------------- --------
  Haplotype                                                                                                                                        
  * DQ2.5*           0.14                     0.520         0.446         1.035 (0.860, 1.249)   0.972      0.446   0.318   1.442 (1.189, 1.748)   0.0003
  * DQ2.2*           0.094                    0.047         0.155         0.255 (0.173, 0.374)   0.422      0.046   0.040   1.201 (0.793, 1.821)   0.381
  * DQ8*             0.1                      0.350         0.064         5.086 (3.883, 6.662)   0.163      0.346   0.392   0.939 (0.779, 1.131)   0.520
   Other             0.663                    0.157         0.260         0.467 (0.366, 0.595)   0.500      0.163   0.249   0.660 (0.530, 0.821)   0.0001
  Genotype                                                                                                                                         
   *DQ2.5*/*DQ2.5*   0.020                    0.176         0.192         0.99 (0.96, 1.02)      0.914      0.168   0.066   1.20 (1.14, 1.26)      0.005
   *DQ2.5*/*DQ2.2*   0.032                    0.039         0.232         0.84 (0.82, 0.87)      7.29E-4    0.039   0.017   1.16 (1.06, 1.27)      0.242
   *DQ2.5*/*DQ8*     0.027                    0.350         0.067         1.47 (1.41, 1.53)      3.31E-10   0.350   0.377   0.98 (0.95, 1.01)      0.681
   *DQ2.5*/other     0.184                    0.150         0.357         0.87 (0.85, 0.90)      1.9E-3     0.168   0.112   1.07 (1.03, 1.11)      0.688
   *DQ2.2*/*DQ2.2*   0.012                    0.005         0.004         1.03 (0.83, 1.28)      0.905      0.004   0.002   1.18 (0.88, 1.58)      0.169
   *DQ2.2*/*DQ8*     0.022                    0.035         0.012         1.22 (1.10, 1.36)      0.189      0.033   0.036   0.98 (0.92, 1.06)      0.908
   *DQ2.2*/other     0.111                    0.012         0.059         0.87 (0.82, 0.92)      0.129      0.010   0.025   0.91 (0.83, 0.99)      0.326
   *DQ8*/*DQ8*       0.009                    0.083         0.010         1.6 (1.46, 1.74)       4.20E-4    0.083   0.078   1.00 (0.96, 1.05)      0.886
   *DQ8*/other       0.135                    0.148         0.031         1.40 (1.32, 1.49)      1.46E-4    0.143   0.216   0.94 (0.91, 0.97)      0.175
   Other/other       0.449                    0.002         0.036         0.85 (0.79, 0.92)      0.166      0.002   0.072   0.84 (0.80, 0.89)      0.028

Freq., frequency.

Conclusions {#s10}
===========

It is possible that a subgroup of patients with T1D or CeD have certain characteristics that predispose them to develop both diseases. However, the larger percentage of individuals developing double autoimmunity than expected based on the prevalence of the individual diseases suggests that common genetic loci and common biological pathways are involved in the pathogenesis of double autoimmunity. By comparing the T1D and CeD GWAS results, we analyzed 12 shared genetic loci both within and outside the MHC-HLA region.

Targeted screening for CeD is recommended in high-risk groups such as children with T1D ([@B27]). Screening for CeD in children is recommended as soon as they develop T1D, and, in the case of a negative outcome, this test should be repeated at well-defined intervals for at least 10 years ([@B10],[@B39]). Untreated CeD carries the risks of iron deficiency anemia, growth retardation, osteoporosis, neuropsychiatric disorders, fertility problems, and gastrointestinal malignancies such as intestinal lymphoma. Genetic risk profiling can contribute to identifying patients with T1D who are predisposed to develop CeD and who might benefit from closer monitoring, as in the majority of cases (\>90%), the diagnosis of T1D precedes that of CeD.

Our aim in the T1DGC Autoantibody Workshop was to enhance the understanding of why a single patient develops two autoimmune diseases by investigating the associated genetic risk factors. In the future, this information might also aid in building genetic risk models to identify individuals with either T1D or CeD who are at high risk of developing double autoimmunity. In our analysis, the HLA locus still presents the most important association with double autoimmunity. However, our association study shows that the HLA haplotypes or genotypes that are related with the risk of double autoimmunity are not the same as those related to the risk of either T1D or CeD in isolation. Individuals with both diseases more closely resemble the patients with T1D only with respect to the frequency of the *DQ2.5*/*DQ8* genotype, which is a well-known risk combination for T1D. The group of *DQ2.5*/*DQ8* carriers is infrequent in the general population (∼2.5%), yet these individuals have a more than fivefold increased risk of developing either T1D or double autoimmunity. Thus, the periodic screening of T1D-related autoantibodies in predominantly CeD patients carrying *DQ2.5*/*DQ8* could be helpful for identifying T1D at an early stage of the disease. The same approach applies to patients with T1D carrying *DQ2.5*/*DQ2.5*, who should be screened for CeD antibodies.

We did not observe a significant enrichment of the shared risk alleles in the group of double autoimmunity patients. In our analysis, we did observe a similar number of CeD-only or T1D-only loci for both study groups. We are aware of the lack of follow-up of the patients but, based on epidemiology, would not have expected a significant increase in the number of unnoticed double autoimmunity patients that could modify the results ([@B40]). We did not find any proof for our hypothesis that known shared genetic risk factors contribute to the coexistence of multiple diseases in the same individual. Nevertheless, *CTLA4* has been associated with multiple autoimmune diseases and has a well-known role in the activation, differentiation, and proliferation of T cells ([@B41]). In our analysis, the *CTLA4* SNP rs3087243 showed a significant association with double autoimmunity in both data sets. While this SNP has not been associated with CeD in GWAS reports, it is in linkage disequilibrium (*r*^2^ = 0.144; D′ = 0.86) with rs4675374, which is associated with CeD risk ([@B19]). These data suggest that *CTLA4* can contribute to the development of double autoimmunity. We also observed the significant association of SNPs located in the *IL2RA* locus. The functional role of *IL2RA* is highly related to *CTLA4,* with a possibly synergistic role, for example, in regulating the activation and differentiation of CD4-positive T cells ([@B42]).

In conclusion, we have shown that there are different genetic associations between patients with double autoimmunity, T1D only, or CeD only. The impact of genetic risk is based, primarily, on specific alleles and genotypes in the HLA class II region, with some support for two genes (*CTLA4* and *IL2RA*) that may be linked through a common immune pathway. The HLA and non-HLA loci found in this study can be used as stratification factors in the construction of risk models to predict double autoimmunity and for pathway enrichment analysis to enhance our understanding of the pathophysiology involved in the development of double autoimmunity. It should be noted that our analysis only included individuals of Caucasian origin. Hence, populations with other genetic backgrounds should be carefully checked, as the results may differ owing to differences in genetic background. The question of how these genetic factors influence the development of double autoimmunity requires further study.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dcs15-2007/-/DC1>.
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